

## Luitpold Pharmaceuticals, Inc. Animal Health Division

**FOR IMMEDIATE RELEASE**

**Contacts:**

Allyn Mann, Luitpold Product Manager  
amann@luitpold.com

**Or** Mary Jane Duff  
(816) 891-8845

[mjduff@theduffcompany.com](mailto:mjduff@theduffcompany.com)

### **PROVEN, FDA-APPROVED ADEQUAN® I.M. NOW AVAILABLE IN MULTI-DOSE VIAL**

SHIRLEY, New York – Luitpold Animal Health announced that the U.S. Food and Drug Administration (FDA) has approved Adequan® i.m. Multi-Dose (polysulfated glycosaminoglycan), a new convenient 10-Dose 50mL vial. After 20 years of proven performance, Adequan® i.m. is the only FDA-approved treatment for non-infectious degenerative joint disease in horses.

The multi-dose single vial contains 5,000 mg of Adequan® i.m., allowing veterinarians to draw ten injections from one vial quickly with less handling compared to the traditional 5mL single-dose vial that is still available in a 7-dose package. The multi-dose package has a 24-month shelf life.



Adequan® i.m. polysulfated glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. It is a potent enzyme inhibitor that diminishes or reverses traumatic or degenerative joint disease which results in a loss of cartilage. Adequan® i.m. improves joint function by reducing synovial fluid protein levels and increasing hyaluronic acid concentration in traumatized equine carpal and hock joints.

After Adequan® i.m. is injected, it reaches peak therapeutic levels in joints in two hours and is detected in cartilage and subchondral bone up to four days. The hyaluronic acid (HA) in the synovial joint fluid nearly doubles within 48 hours of injection. The recommended dose is 5 mL every four days for seven treatments.

“Adequan is the only complete treatment for joints. Literally, it’s a class by itself” says Allyn Mann, Senior Manager of the Animal Health Division of Luitpold Pharmaceuticals, Inc. “It offers the benefits of other joint products, but it is the only product that stops the joint disease cycle, blocks destructive enzymes, stimulates cartilage repair and reverses traumatic joint dysfunction,” he explains. Veterinarians now have the choice of single dose 5 mL vials packaged in boxes of seven for a complete treatment and the new 50 mL Multi-dose vial.

For more information and full prescribing information, visit [www.adequan.com](http://www.adequan.com).

##

Luitpold Pharmaceuticals, Inc. Animal Health Division based in Shirley, N.Y., markets Adequan® i.m., Adequan® i.a. (POLYSULATED GLYCOSAMINOGLYCAN) and Equiphen® Paste (PHENYBUTAZONE) for horses. The company is committed to advancing the cause of equine health. For more information about products from Luitpold Animal Health visit [www.luitpoldanimalhealth.com](http://www.luitpoldanimalhealth.com).

There are no known contraindications to the use of intramuscular PSGAG in horses. The safe use of Adequan® i.m. Multi-Dose in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Burba DJ, Collier MA, Default LE, Hanson-Printon O, Thompson HC, Holder CL: IN VIVO KINETIC STUDY ON UPTAKE AND DISTRIBUTION OF INTRAMUSCULAR TRITIUM-LABELED POLYSULFATED GLYCOSAMINOGLYCAN IN EQUINE BODY FLUID COMPARTMENTS AND ARTICULAR CARTILAGE IN AN OSTEOCHONDRAL DEFECT MODEL. The Journal of Equine Veterinary Science 1993; 696-703.

\*Concentrations of Adequan i.m. in the synovial fluid begin to decline after peak levels are reached at 2 hours; then remain constant from 24 hours post injection through 96 hours.